Pulmonary arterial hypertension is a subset of the group of diseases known as pulmonary hypertension (PH), which can be a consequence of other diseases or manifest idiopathically. The recent rapid evolution of diagnostic techniques and pharmacotherapies have resulted in renewed interest in PH. Treatment of the disease can be complex and is an opportune area for pharmacist involvement. As diagnostics have improved over the years, the prevalence of this disease is becoming more common place. Accordingly, clinical pharmacists need to be comfortable with the available therapies and factors that influence the quality of care provided to persons with pulmonary hypertension. Treatment selection can be a complex process and is often dependent on the etiology of the disease. Factors considered for treatment selection include the patient comorbidities, access to proper care, the ability of care providers to navigate risk evaluation and mitigation systems, and the affordability of therapies to patients. By the end of this program, attendees will be more familiar with the etiologies, diagnosis, and treatment of pulmonary arterial hypertension. Post program, learners will be better equipped to help their patients to navigate this disease and the complexity of care it involves.

Faculty

Moderator: Jeffrey Gonzales, Pharm.D., BCPS, PDE-C, CDCES Clinical Pharmacy Specialist, Transitions of Care. St. Mary Medical Center, Langhorne PA.   View Biography